XM n’offre pas ses services aux résidents des États-Unis d’Amérique.

XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
B
B

Biomerieux

Actualités

Reuters - Il y a 3 semaines

Biomerieux Receives FDA 510(K) Clearance Of VIDAS TBI

BRIEF-Biomerieux Receives FDA 510(K) Clearance Of VIDAS TBI May 28 (Reuters) - Biomerieux SA BIOX.PA : BIOMERIEUX SA - RECEIVES FDA 510(K) CLEARANCE OF VIDAS TBI (GFAP, UCH-L1) Source text for Workspace: ID:nNDLs53Tm Further company coverage: BIOX.PA (Gdansk Newsroom)
B
Reuters - Il y a 3 semaines

Malawi Health Ministry, bioMerieux, Pfizer Form Multisectoral Collaboration On Antimicrobial Resistance

BRIEF-Malawi Health Ministry, bioMerieux, Pfizer Form Multisectoral Collaboration On Antimicrobial Resistance May 23 (Reuters) - Biomerieux SA BIOX.PA : MALAWI MINISTRY OF HEALTH, BIOMÉRIEUX, AND PFIZER FORM COUNTRY'S FIRST MULTISECTORAL COLLABORATION TO HELP ADDRESS ANTIMICROBIAL RESISTANCE Source textL https://tinyurl.com/46ayacaa Further compan
B
P
Reuters - Il y a 1 mois

Barclays starts Biomerieux at 'overweight,' notes smoother growth among peers

BUZZ-Barclays starts Biomerieux at 'overweight,' notes smoother growth among peers ** Barclays initiates the French diagnostics specialist Biomerieux BIOX.PA with "overweight", saying that its organic growth has been "smoother" than the broader in vitro diagnostics peer group ** "The company has managed to grow revenues vs its 2021 base despite COV
B
D
Reuters - Il y a 1 mois

Barclays cites DiaSorin's in-line top-line but 'ambitious' margins - starts at 'equal weight'

BUZZ-Barclays cites DiaSorin's in-line top-line but 'ambitious' margins - starts at 'equal weight' ** Barclays initiates coverage of DiaSorin DIAS.MI with "equal weight", seeing its top-line 9% CAGR revenue estimate for 2024-27 to be in line with the company's mid-term guidance and driven by the launch of new products ** However, the Italian diagno
B
D
Reuters - Il y a 1 mois

Arkema, Fuller Smith & Turner, Siemens Energy

EUROPE RESEARCH ROUNDUP- Arkema, Fuller Smith & Turner, Siemens Energy May 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Fuller Smith & Turner and Siemens Energy, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 117 from EUR 107 * Bytes Technology Group Plc BYIT.L : Deutsche Bank initiates coverage with buy rating * Fuller Smith & Turner Plc FSTA.L : Deutsche Bank initiates coverage with buy
A
A
A
A
B
B
B
B
C
E
E
G
A
A
B
D
G
Reuters - Il y a 2 mois

Dassault Systemes, Husqvarna, Swedbank

EUROPE RESEARCH ROUNDUP-Dassault Systemes, Husqvarna, Swedbank April 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Dassault Systemes, Husqvarna and Swedbank on Friday. HIGHLIGHTS * AstraZeneca AZN.L : Deutsche Bank raises target price to 11000p from 10500p * Dassault Systemes DAST.PA : JP Morgan cuts to neutral from overweight * Husqvarna AB HUSQb.ST : Jefferies raises to buy from hold * London Stock Exchange Group LSEG.L : RB
A
A
A
A
A
A
A
A
A
A
A
B
B
B
B
B
D
D
F
H
I
N
R
S
V
A
A
A
B
B
B
E
F
S
Reuters - Il y a 2 mois

Top of the Street: Galp, Reckitt, Legrand, Biomerieux

BUZZ-Top of the Street: Galp, Reckitt, Legrand, Biomerieux A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Morgan Stanley upgrades Portugal's Galp GALP.LS to "equal-weight" from "underweight", saying its call on Galp has been unsuccessful as the Namibia exploration campaign results have consistently exceeded assumptions ** Jefferies ups Reckitt RKT.L to "hold" from "underperform" as they expect the Enfamil maker to be more supported in H2, when the group
B
L
G
Reuters - Il y a 2 mois

Adriatic Metals, Diageo, GB Group

EUROPE RESEARCH ROUNDUP-Adriatic Metals, Diageo, GB Group April 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adriatic Metals, Diageo and GB Group, on Tuesday. HIGHLIGHTS * Adriatic Metals Plc ADT1.L : Stifel raises target price to 275p from 250p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2400p from 2430p * GB Group Plc GBGP.L : Peel Hunt raises target price to 360p from 340p * H&M HMb.ST : Morgan Stanley raises
A
B
B
D
D
D
G
H
I
L
P
H
G
Reuters - Il y a 2 mois

Bytes Technology, Marks and Spencer, Phoenix

EUROPE RESEARCH ROUNDUP-Bytes Technology, Marks and Spencer, Phoenix April 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bytes Technology, Marks and Spencer and Phoenix, on Monday. HIGHLIGHTS * Adidas AG ADSGn.DE : RBC raises target price to EUR 250 from EUR 230 * Bytes Technology Group Plc BYIT.L : HSBC raises to buy from hold * Marks and Spencer Group MKS.L : Jefferies raises to buy from hold * Phoenix PHNX.L : Berenberg cut
A
A
A
A
B
B
B
B
E
E
E
E
G
L
L
M
N
P
R
U
A
A
B
B
D
G
I
I
M
R
Reuters - Il y a 2 mois

Alfen, Boliden, Pennon Group

EUROPE RESEARCH ROUNDUP-Alfen, Boliden, Pennon Group April 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfen, Boliden and Pennon Group on Wednesday. HIGHLIGHTS * Alfen ALFEN.AS : Deutsche Bank cuts to hold from buy * Boliden AB BOL.ST : JP Morgan raises to neutral from underweight * Pennon Group Plc PNN.L : RBC raises to outperform rating * Picton Property Income Ltd PCTN.L : Peel Hunt raises to buy from hold * URW URW.PA :
A
A
A
B
B
B
B
B
B
C
C
E
E
E
F
G
H
H
L
N
P
A
A
B
B
B
D
Reuters - Il y a 2 mois

BASF, Cadeler, Edenred

EUROPE RESEARCH ROUNDUP-BASF, Cadeler, Edenred April 10 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including BASF, Cadeler and Edenred, on Wednesday. HIGHLIGHTS * BASF BASFn.DE : Deutsche Bank cuts to hold from buy * Cadeler A/S CADLR.OL : Jefferies raises target price to NOK 70 from NOK 65 * Edenred EDEN.PA : Jefferies initiates coverage with underperform rating; PT EUR 40 * Troax Group AB (Publ) TROAX.ST : Berenberg initiates coverage
A
A
A
B
B
B
E
E
E
G
H
H
I
I
K
L
M
P
R
R
R
S
S
S
S
S
V
W
B
M
S
Reuters - Il y a 2 mois

Slide in defence stocks knocks down Europe's STOXX 600

UPDATE 2-Slide in defence stocks knocks down Europe's STOXX 600 For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window BP gains on higher quarterly upstream energy output forecast Fincantieri shines after Norwegian Cruise Line deal Italy cuts growth forecasts and says debt set to rise Updates with closing prices By Ankika Biswas, Johann M Cherian and Ozan Ergenay April 9 (Reuters) - A sell-off in defence stocks dragged Europe's benchmark stock
A
B
B
L
R
T
A
F
E
F
I
U
G
Reuters - Il y a 2 mois

Biomerieux shares eye best day in 25 mths after better-than-expected Q1

BUZZ-Biomerieux shares eye best day in 25 mths after better-than-expected Q1 ** Shares in Biomerieux BIOX.PA rise 8%, set for best day in 25 months if gains hold, after the company published Q1 organic growth above consensus, and presented new 5-year strategic plan ** The French diagnostics specialist reports Q1 sales of 965.2 million euros ($1.05
B
Reuters - Il y a 2 mois

European shares off to a gloomy start

LIVE MARKETS-European shares off to a gloomy start Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPEAN SHARES OFF TO A GLOOMY START European shares were trading lower on Tuesday, with investors remaining cautious ahead of this week's U.S.
A
B
A
R
E
F
U
G
Reuters - Il y a 2 mois

Biomerieux Aims At Organic Revenue Growth Of +7% 2028

BRIEF-Biomerieux Aims At Organic Revenue Growth Of +7% CAGR 2024-2028 April 9 (Reuters) - Biomerieux SA BIOX.PA : AIMS AT ORGANIC REVENUE GROWTH OF +7%, CAGR2 2024 / 2028 2028 PLAN : DIVIDEND PAY-OUT RATIO POLICY OF AROUND 25% OF THE ANNUAL GROUP NET INCOME GO 28 PLAN: CONTRIBUTIVE OPERATING INCOME BEFORE NON RECURRING ITEMS IMPROVING TO 20% OF SAL
B
Reuters - Il y a 2 mois

Biomerieux Q1 Consolidated Sales Up 6.6% At EUR 965 Million

BRIEF-Biomerieux Q1 Consolidated Sales Up 6.6% At EUR 965 Million April 9 (Reuters) - Biomerieux SA BIOX.PA : CONFIRMS ITS 2024 GUIDANCE FOR SALES AND OPERATING PROFIT, TARGETING AN ORGANIC SALES GROWTH BETWEEN +6% AND +8%, AND A CONTRIBUTIVE OPERATING INCOME BEFORE NONRECURRING ITEMS GROWING AT LEAST BY +10% AT CONSTANT EXCHANGE RATES CONSOLIDATED
B
Reuters - Il y a 3 mois

Berenberg upgrades Biomerieux on growth potential

BUZZ-Berenberg upgrades Biomerieux on growth potential ** Berenberg upgrades Biomerieux BIOX.PA to "buy" from "hold" as it expects new product launches to drive growth for the French diagnostics company ** It points to a "remarkably strong" Q4 performance of Biomerieux's new product in molecular infectious disease diagnostics, SPOTFIRE ** The broke
B
Reuters - Il y a 3 mois

Biomerieux, Pernod Ricard, Remy Cointreau

EUROPE RESEARCH ROUNDUP-Biomerieux, Pernod Ricard, Remy Cointreau March 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Biomerieux, Pernod Ricard and Remy Cointreau, on Thursday. HIGHLIGHTS * Biomerieux SA BIOX.PA : Berenberg raises to buy from hold * Diasorin SpA DIAS.MI : Berenberg cuts to hold from buy * Pernod Ricard PERP.PA : Deutsche Bank raises to hold from sell * Remy Cointreau RCOP.PA : Deutsche Bank raises to buy from
A
A
B
B
C
C
C
C
C
D
E
H
H
I
I
R
R
S
A
A
B
D
P
S
Reuters - Il y a 3 mois

Aston Martin, Bodycote, Systemair

EUROPE RESEARCH ROUNDUP- Aston Martin, Bodycote, Systemair March 18 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Aston Martin, Bodycote, and Systemair, on Monday. HIGHLIGHTS * Aston Martin AML.L : Jefferies cuts target price to 275p from 330p * Bodycote Plc BOY.L : JP Morgan raises target price to 620p from 600p * Novo Nordisk NOVOb.CO : Berenberg raises target price to DKK 900 from DKK 850 * Systemair AB SYSR.ST : Jefferies rais
A
A
A
A
A
B
B
B
B
C
C
C
C
D
E
E
E
G
H
I
L
L
P
P
S
A
A
A
A
D
P
U

Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques